Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Sermorelin vs Tesamorelin + Ipamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than Sermorelin (Discontinued (FDA approval 1990; US withdrawal 2008)) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. Sermorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Sermorelin

Discontinued (FDA approval 1990; US withdrawal 2008)

Tesamorelin + Ipamorelin

FDA-Approved (component)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Sermorelin Tesamorelin + Ipamorelin
Class GHRH analog FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover.
Route SC injection SC injection
Half-life ~10-20 min Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs
Dosage (research) 200-500 mcg SC at bedtime daily 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off
Evidence tier Discontinued (FDA approval 1990; US withdrawal 2008) FDA-Approved (component)
Research depth 149 indexed (PubMed 122 · CT 17 · EPMC 10) —
Availability Compounding Restricted Compounding Restricted
Reported risks Injection site reactions; headache; flushing Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive)

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Sermorelin or Tesamorelin + Ipamorelin?

Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than Sermorelin (Discontinued (FDA approval 1990; US withdrawal 2008)) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. Sermorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Sermorelin and Tesamorelin + Ipamorelin?

Sermorelin is classed as GHRH analog; Tesamorelin + Ipamorelin is classed as FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Reported mechanism: Sermorelin, Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release; Tesamorelin + Ipamorelin, Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. Reported half-life: Sermorelin, ~10-20 min; Tesamorelin + Ipamorelin, Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs. Routes in published studies: Sermorelin, SC injection; Tesamorelin + Ipamorelin, SC injection.

Which has stronger evidence, Sermorelin or Tesamorelin + Ipamorelin?

Tesamorelin + Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Sermorelin is graded Discontinued (FDA approval 1990; US withdrawal 2008), with 6 cited sources on its reference page and 149 indexed studies. Tesamorelin + Ipamorelin is graded FDA-Approved (component), with 3 cited sources on its reference page.

Which is more accessible, Sermorelin or Tesamorelin + Ipamorelin?

Neither Sermorelin nor Tesamorelin + Ipamorelin is an FDA-approved drug. Catalog status: Sermorelin, Compounding Restricted; Tesamorelin + Ipamorelin, Compounding Restricted.

Are Sermorelin and Tesamorelin + Ipamorelin ever combined?

Sermorelin and Tesamorelin + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…